uracil has been researched along with Myasthenia Gravis in 4 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inhibition of human AChE (acetylcholinesterase) and BChE (butyrylcholinesterase) by an alkylammonium derivative of 6-methyluracil, C-547, a potential drug for the treatment of MG (myasthenia gravis) was studied." | 7.83 | Slow-binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6-methyluracil: mechanism and possible advantages for myasthenia gravis treatment. ( Kharlamova, AD; Kots, ED; Krejci, E; Lushchekina, SV; Masson, P; Nachon, F; Nikolsky, EE; Petrov, KA; Reznik, VS; Villard-Wandhammer, M; Zobov, VV; Zueva, IV, 2016) |
| "Inhibition of human AChE (acetylcholinesterase) and BChE (butyrylcholinesterase) by an alkylammonium derivative of 6-methyluracil, C-547, a potential drug for the treatment of MG (myasthenia gravis) was studied." | 3.83 | Slow-binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6-methyluracil: mechanism and possible advantages for myasthenia gravis treatment. ( Kharlamova, AD; Kots, ED; Krejci, E; Lushchekina, SV; Masson, P; Nachon, F; Nikolsky, EE; Petrov, KA; Reznik, VS; Villard-Wandhammer, M; Zobov, VV; Zueva, IV, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saifina, LF | 3 |
| Abdalla, M | 3 |
| Gubaidullina, LM | 3 |
| Zueva, IV | 4 |
| Eltayb, WA | 3 |
| El-Arabey, AA | 3 |
| Kharlamova, AD | 4 |
| Lenina, OA | 3 |
| Semenov, VE | 3 |
| Petrov, KA | 4 |
| Petrov, K | 1 |
| Zueva, I | 1 |
| Kovyazina, I | 1 |
| Sedov, I | 1 |
| Lushchekina, S | 1 |
| Kharlamova, A | 1 |
| Lenina, O | 1 |
| Koshkin, S | 1 |
| Shtyrlin, Y | 1 |
| Nikolsky, E | 1 |
| Masson, P | 2 |
| Lushchekina, SV | 1 |
| Kots, ED | 1 |
| Nachon, F | 1 |
| Villard-Wandhammer, M | 1 |
| Krejci, E | 1 |
| Reznik, VS | 1 |
| Zobov, VV | 1 |
| Nikolsky, EE | 1 |
| KUSTOV, VV | 1 |
4 other studies available for uracil and Myasthenia Gravis
| Article | Year |
|---|---|
Novel slow-binding reversible acetylcholinesterase inhibitors based on uracil moieties for possible treatment of myasthenia gravis and protection from organophosphate poisoning.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Kinetics; Myastheni | 2023 |
Novel slow-binding reversible acetylcholinesterase inhibitors based on uracil moieties for possible treatment of myasthenia gravis and protection from organophosphate poisoning.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Kinetics; Myastheni | 2023 |
Novel slow-binding reversible acetylcholinesterase inhibitors based on uracil moieties for possible treatment of myasthenia gravis and protection from organophosphate poisoning.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Kinetics; Myastheni | 2023 |
Novel slow-binding reversible acetylcholinesterase inhibitors based on uracil moieties for possible treatment of myasthenia gravis and protection from organophosphate poisoning.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Kinetics; Myastheni | 2023 |
C-547, a 6-methyluracil derivative with long-lasting binding and rebinding on acetylcholinesterase: Pharmacokinetic and pharmacodynamic studies.
Topics: Acetylcholinesterase; Albumins; Animals; Cholinesterase Inhibitors; Diffusion; Disease Models, Anima | 2018 |
Slow-binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6-methyluracil: mechanism and possible advantages for myasthenia gravis treatment.
Topics: Acetylcholinesterase; Animals; CHO Cells; Cholinesterase Inhibitors; Cricetinae; Cricetulus; Humans; | 2016 |
[Result of pentoxyl therapy of leukopenia caused by intensive roentgenologic irradiation in syringomyelia and myasthenia].
Topics: Humans; Leukocyte Count; Leukocyte Disorders; Leukopenia; Myasthenia Gravis; Pentoxyl; Syringomyelia | 1955 |